Mostrando 10 resultados de: 47
Filtros aplicados
Publisher
Pharmacogenomics Journal(12)
Pharmacogenomics(11)
Drug Metabolism and Drug Interactions(6)
European Journal of Clinical Pharmacology(2)
Expert Opinion on Drug Metabolism and Toxicology(2)
Challenges and Opportunities for Clinical Pharmacogenetic Research Studies in Resource-limited Settings: Conclusions From the Council for International Organizations of Medical Sciences–Ibero-American Network of Pharmacogenetics and Pharmacogenomics Meeting
ArticleAbstract: Purpose: The symposium Health and Medicines in Indigenous Populations of America was organized by thPalabras claves:CIOMS-RIBEF, clinical research, pharmacogenetics, resource-limited settingsAutores:Adrián LLerena, Diwakar S., Enrique Terán, Galaviz-Hernandez C., Gil J.P., Isabel Hernández, Lara-Riegos J., Molina-Guarneros J.A., Moya G.E., Nair S., Penãs-Lledó E.M., Rägo L., Ramírez-Roa R., Sosa-Macías M.G., Tarazona-Santos E.M., Verde I.Fuentes:googlescopusClinical implications of CYP2D6 genetic polymorphism during treatment with antipsychotic drugs
ReviewAbstract: CYP2D6 is described as the most relevant enzyme in the metabolism of many antipsychotic drugs. Its cPalabras claves:Antipsychotic drugs, CYP2D6, pharmacogenetics, PharmacogenomicsAutores:Adrián LLerena, Berecz R., Cáceres M.C., Dorado P., Penãs-Lledó E.M.Fuentes:scopusClinical use of pre-emptive pharmacogenetic programmes
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Penãs-Lledó E.M.Fuentes:scopusAntipsychotic drugs and QTc prolongation: The potential role of CYP2D6 genetic polymorphism
ReviewAbstract: Although the most common, and usually serious, side effects of first-generation (or typical) antipsyPalabras claves:Antipsychotic drugs, Cardiac side effects, CYP2D6, drug metabolism, QT interval lengthening, Torsades de pointes-type arrhythmiaAutores:Adrián LLerena, Berecz R., Dorado P., Penãs-Lledó E.M.Fuentes:scopusDevelopment of a HPLC method for the determination of losartan urinary metabolic ratio to be used for the determination of CYP2C9 hydroxylation phenotypes
ArticleAbstract: Background: Losartan is metabolized to losartan carboxylic acid (E-3174) by the polymorphic cytochroPalabras claves:CYP2C9*Hispanics, LOSARTÁN, pharmacogenetics, PhenotypeAutores:Adrián LLerena, de Andrés F., Dorado P., Machín E., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusCYP2C9, CYP2C19, ABCB1 genetic polymorphisms and phenytoin plasma concentrations in Mexican-Mestizo patients with epilepsy
ArticleAbstract: We aimed to explore the possible influence of CYP2C9 (∗2, ∗3 and IVS8-109 A>T), CYP2C19 (∗2, ∗3 andPalabras claves:Autores:Adrián LLerena, Dorado P., Familiar-López I., Fricke-Galindo I., Jung-Cook H., López-López M., Martínez-Juárez I.E., Monroy-Jaramillo N., Ortega-Vázquez A., Penãs-Lledó E.M.Fuentes:scopusCYP2D6 ethnic variability in hispanics
Book PartAbstract: Genetic polymorphism in the CYP2D6 gene results in a wide variability in CYP2D6 enzymatic activity,Palabras claves:Autores:Adrián LLerena, Dorado P., Naranjo M.E.G., Penãs-Lledó E.M.Fuentes:scopusCYP2D6 genetic polymorphism and psychiatry patients' hospitalization period
OtherAbstract:Palabras claves:Autores:Adrián LLerena, Penãs-Lledó E.M.Fuentes:scopusCYP2D6 genetic polymorphisms in Southern Mexican Mayan Lacandones and Mestizos from Chiapas
ArticleAbstract: Aim: In previous CYP2D6 genotyping studies in Mexican-Amerindians a very low frequency of poor metabPalabras claves:CYP2D6, Lacandones, Mexican-Mestizo, pharmacogeneticsAutores:Adrián LLerena, Alonso E., Dorado P., López-López M., Ochoa-Morales A., Ortega A., Penãs-Lledó E.M., Vázquez T.C., Yescas-Gómez P.Fuentes:scopusCYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans
ArticleAbstract: CYP2D6 genotype and debrisoquine metabolic ratio (MR) were analyzed in 133 Nicaraguan Mestizos (NMs)Palabras claves:Cubans, CYP2D6, debrisoquine hydroxylation, Latinos, Nicaraguans, PhenotypeAutores:Adrián LLerena, Alvárez M., Calzadilla L.R., Dorado P., González I., Penãs-Lledó E.M., Pérez B., Ramirez R.Fuentes:scopus